Dual-Diagnosis and Compulsory Treatment

April 15, 2014 updated by: Sorlandet Hospital HF

Compulsory Treatment of Alcohol and Drug Dependent Patients and Dual Diagnosis in 5 Counties of Health Region South-East, Norway

The Norwegian Social and Welfare Act of 1992, opened for compulsory commitment of patients with serious alcohol and drug problems to inpatient care. Clinical research of compulsory committed dual diagnosed patients is to date unavailable and is demanded by the health authorities of Norway. Because there has been limited examination/screening and no post-treatment research efforts on this group of patients, the investigators have limited knowledge of the treatment as well as the patient group. Do compulsory treated patients differ from those voluntarily admitted? Does this type of treatment influence the patients' motivation to change their behaviour, and does the treatment effort lead to positive outcome effects in the long run?

The primary aim is to acquire new and in depth descriptive knowledge about the compulsory treated group of patients according to: Drug dependence, psychiatric and somatic co-morbidity and socio-demographic characteristics, and investigate whether the treatment yields the intended outcomes in terms of improved substance abuse measures.

A second aim is to compare the group with a corresponding group of voluntarily admitted patients within the same wards. A follow-up interview focusing on motivational issues within 6 months post treatment to evaluate the long-term results of the treatment is planned.

A quasi-experimental, prospective case-control study will be conducted. Compulsory committed patients in five counties during a two year period, will be compared to a group of voluntarily admitted patients. The groups will be compared regarding 1) description and screening 2) motivation to change and 3) outcome results after 6 months.

Both official authorities as well as clinical practitioners would benefit from valid Norwegian results and knowledge within this field to form further policies and evidence based best practice for this vulnerable group of patients.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

202

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Vest Agder
      • Kristiansand, Vest Agder, Norway, 4604
        • Sorlandet hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

In five counties there are a total of eight beds reserved for compulsory treatment according to the LOST § 6.2 regulation. Of these, four are situated at the Addiction Unit at Sørlandet Hospital (Kristiansand) and four at the Vestfold Clinic, part of the psychiatric section in the county of Vestfold, Tønsberg. It will be necessary to include both sites for two years of inclusion in this study to obtain sufficient samples, as there are only approximately 35 patients in the compulsory committed category annually in this region. All eligible patients compulsory committed to the two wards in Kristiansand and Tønsberg during a twenty-four month period will be asked to participate during their initial assessment.

Description

Inclusion Criteria:

  • Patients with alcohol and substance use disorders
  • Estimated premorbid IQ of 70 or higher

Exclusion Criteria:

  • Active drug or alcohol abuse

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Involuntary patients
Compulsory treated patients according to the Norwegian Social and Welfare Act of 1992. Most patients have dualdiagnosis.
Voluntary patients
Voluntary patients on the same wards. Most patients have dual-diagnosis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Substance use outcomes measured by Europ-ASI Quality of Life
Time Frame: 6 months after discharge
6 months after discharge

Secondary Outcome Measures

Outcome Measure
Time Frame
Psychological distress (SCL-90-R)
Time Frame: 6 months after discharge
6 months after discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Øistein Kristensen, Sørlandet Sykehus HF

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2008

Primary Completion (Actual)

May 1, 2012

Study Completion (Actual)

May 1, 2012

Study Registration Dates

First Submitted

September 1, 2009

First Submitted That Met QC Criteria

September 1, 2009

First Posted (Estimate)

September 2, 2009

Study Record Updates

Last Update Posted (Estimate)

April 16, 2014

Last Update Submitted That Met QC Criteria

April 15, 2014

Last Verified

April 1, 2014

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • SSHF_815360

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Substance-Related Disorders

3
Subscribe